Post by Biomed Industries Inc

Biomed Industries, Inc., a clinical-stage biopharmaceutical company developing next-generation therapies for obesity and metabolic disorders, today announced continued advancement of NA-931, a proprietary oral investigational therapy designed to deliver clinically meaningful weight reduction while supporting lean-mass preservation.   “Obesity therapeutics have reached a new era of efficacy, but adoption at global scale still faces major barriers,” said Dr. Lloyd L. Tran, Chief Executive Officer of Biomed Industries. “NA-931 is being developed as a next-generation oral therapy intended to eliminate injections entirely, improve long-term persistence, and support healthier body composition outcomes—including lean-mass preservation.” Learn more at: https://lnkd.in/g_hS8KfN